Pamrevlumab did not meet its primary endpoint for non-ambulatory patients with Duchenne Muscular Dystrophy: the LELANTOS-1 trialAnne M. Connolly, Ewa Carrier, H. Phan et al.|medRxiv|2025Cited by 3